CRINETICS PHARMACEUTICALS, INC. (CRNX)
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
📈 **POSITIVE** • Medium confidence analysis (79%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (93%) **Content type:** Clinical